Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2024.08.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effective use of dupilumab for eosinophilic gastritis concomitant with severe asthma.
Allergy Asthma Clin Immunol
December 2024
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, 3-1-3, Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.
Background: Eosinophilic gastrointestinal diseases (EGIDs) are chronic immune-mediated inflammatory disorders characterized by gastrointestinal symptoms and eosinophilic inflammation in specific regions of the gastrointestinal tract. "Eosinophilic gastritis" (EoG) refers to the condition in which the stomach is involved. In patients with EoG, approved treatment options are restricted despite the high mortality associated with the condition.
View Article and Find Full Text PDFA Case of Upadacitinib-Associated Ileus Secondary to Psoriasis Induced by Treatment of Atopic Dermatitis with Dupilumab.
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Peking University People's Hospital, Beijing, 100044, People's Republic of China.
A 69-year-old man with severe atopic dermatitis (AD) received a single 600 mg subcutaneous injection of dupilumab, which resulted in a psoriatic rash on day 10. He was then given 30 mg of oral upadacitinib daily, and after 10 weeks of treatment, both the AD and the psoriasis had significantly improved. However, at week 16, the patient had no bowel movement for a week, and paralytic ileus was suspected based on the patient's symptoms and laboratory findings.
View Article and Find Full Text PDFLong-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics.
ERJ Open Res
November 2024
Sanofi, Bridgewater, NJ, USA.
https://bit.ly/3XSwX62.
View Article and Find Full Text PDFClinical, histological and safety outcomes with long-term maintenance therapies for eosinophilic esophagitis: A systematic review and meta-analysis.
Clin Gastroenterol Hepatol
December 2024
Gastroenterology and Digestive Endoscopy, IRCCS Ospedale San Raffaele.
Background And Aim: Our aim was to evaluate outcomes of maintenance treatments for EoE among observational studies (OSs) and randomized controlled trials (RCTs).
Materials And Methods: Studies reporting histological success of maintenance therapy ≥ 48 weeks were included. Primary outcome was histological success rate (defined as <15/<6 eos/HPF).
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.
Allergy
December 2024
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
Background: Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved safety and desensitization to peanut exposure in children with peanut allergy.
Methods: A Phase II, 24-week, multicenter, single-arm, open-label, proof-of-concept study was conducted in the USA and Canada (NCT03793608).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!